Health First Inc. filed on December 18, 2018.; Petitioner seeks a Declaratory Statement from the Board to declare that Pettioner’s Penicillin Skin Testing (“PST”) program, as outlined in the petition, may be undertaken by the Petitioner’s hospital ...

 

DEPARTMENT OF HEALTH

Board of Pharmacy

RULE NO.:RULE TITLE:

64B16-27.810Prospective Drug Use Review

64B16-27.830Standards of Practice - Drug Therapy Management

NOTICE IS HEREBY GIVEN that the Board of Pharmacy has received the petition for declaratory statement from Health First Inc. filed on December 18, 2018.The petition seeks the agency's opinion as to the applicability of Rules 64B16-27.830 and 64B16-27.810, F.A.C., as it applies to the petitioner.

Petitioner seeks a Declaratory Statement from the Board to declare that Pettioner’s Penicillin Skin Testing (“PST”) program, as outlined in the petition, may be undertaken by the Petitioner’s hospital pharmacists under the auspices of the Drug Therapy Management Rule 64B16-27.830, F.A.C., and the Prospective Drug Utilization Review Rule 64B16-27.810, F.A.C. Except for good cause shown, motions for leave to intervene must be filed within 21 days after the publication of this notice.

A copy of the Petition for Declaratory Statement may be obtained by contacting: C. Erica White, Executive Director, Board of Pharmacy, 4052 Bald Cypress Way, Bin C04, Tallahassee, Florida 32399-3254or by email at [e-mail].